Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,662 as of Friday, May 30, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,201 issues advancing vs. 1,742 declining with 169 unchanged. The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Pharmacyclics ( PCYC), up 2.4%, and AstraZeneca ( AZN), up 0.9%. On the negative front, top decliners within the industry include Alexion Pharmaceuticals ( ALXN), down 1.9%, Illumina ( ILMN), down 1.8%, Valeant Pharmaceuticals International ( VRX), down 1.5%, Shire ( SHPG), down 1.3% and Actavis ( ACT), down 1.2%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Dr Reddy Laboratories ( RDY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Dr Reddy Laboratories is up $1.06 (2.6%) to $41.12 on heavy volume. Thus far, 367,340 shares of Dr Reddy Laboratories exchanged hands as compared to its average daily volume of 359,700 shares. The stock has ranged in price between $40.72-$41.49 after having opened the day at $41.14 as compared to the previous trading day's close of $40.06. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. Dr Reddy Laboratories has a market cap of $6.7 billion and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Thursday. Currently there is 1 analyst who rates Dr Reddy Laboratories a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Dr Reddy Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full Dr Reddy Laboratories Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.